Overview

Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors

Status:
Recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

The aim of the COMBINATION trial is to prospectively study the sequential approach of using afatinib combined with a short course of chemotherapy, followed by osimertinib, upon progression and acquisition of a T790M mutation, also combined with a short course of chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

VU University Medical Center

Treatments:

Afatinib
Carboplatin
Osimertinib
Pemetrexed